首页> 外国专利> Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome

机译:adamts13在治疗,改善和/或预防镰状细胞病,急性肺损伤和/或急性呼吸窘迫综合征中的血管闭塞性危机中的用途

摘要

The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
机译:本公开内容提供了用于治疗,改善和/或预防患有镰状细胞疾病(SCD)的受试者的血管闭塞性危机(VOC)的组合物和方法。本公开内容还提供了用于治疗,改善和/或预防患有急性肺损伤(ALI)和/或急性呼吸窘迫综合征(ARDS)或有遭受其风险的受试者的肺损伤的组合物和方法。本公开内容提供了具有血小板反应蛋白1型基序的成员13的整联蛋白和金属蛋白酶(ADAMTS13)或包含ADAMTS13的组合物,其用于治疗,改善和/或预防VOC,或用于治疗,改善和/或预防肺损伤。患有ALI和/或ARDS或有遭受ALI和/或ARDS风险的对象。

著录项

  • 公开/公告号IL264372D0

    专利类型

  • 公开/公告日2019-02-28

    原文格式PDF

  • 申请/专利权人 BAXALTA INCORPORATED;BAXALTA GMBH;

    申请/专利号IL20190264372

  • 发明设计人

    申请日2019-01-21

  • 分类号A61K;

  • 国家 IL

  • 入库时间 2022-08-21 12:02:09

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号